Skip to main content
Premium Trial:

Request an Annual Quote

Jai Nagarkatti and Jeffrey Price

Premium

Sigma-Aldrich announced last week that Jai Nagarkatti, president of the company’s scientific research business unit, has been elected president and chief operating officer. He replaces David Harvey, who will continue as chairman of the board and chief executive officer. Three business units — scientific research, biotechnology, and fine chemicals — will now report to Nagarkatti.

Nagarkatti’s 28-year career at Sigma-Aldrich has spanned R&D, manufacturing, operations, and sales and marketing, the company said. Prior to his role as president of the scientific research business unit, he was president of the fine chemicals business. Nagarkatti holds an MS in chemistry from Osmania University in India, and a PhD in organic chemistry from Texas A&M University-Commerce.


Jeffrey Price has accepted a faculty position at the Burnham Institute, Inside Bioassays has learned. Price joins the Burnham Institute from the University of California, San Diego, where he was an associate research scientist in the department of bioengineering, and director of the Whitaker Foundation Confocal Microscopy Resource.

Price also told Inside Bioassays that he is forming a new biotech startup company, Vala Sciences. He previously founded Q3DM, a startup that specialized in automated microscopy and was purchased by Beckman Coulter late last year. Price also served as a consultant to Beckman Coulter following the deal. He holds an MD from Loma Linda University, and a PhD from UCSD.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.